Case Study
Science 37 Accelerates Timelines and Expands Reach in Infectious Disease Study.
Study enrollment rates have declined by more than 50% from pre-pandemic levels. To meet today’s challenges, the Science 37 Metasite™ expands your access to untapped patient populations and liberates you from geography and diversity limitations. With a site that visits the patient, you’ll accelerate study recruitment and enrollment, while delivering high-quality data.
Study enrollment rates have declined by more than 50% from pre-pandemic levels. To meet today’s challenges, the Science 37 Metasite™ expands your access to untapped patient populations and liberates you from geography and diversity limitations. With a site that visits the patient, you’ll accelerate study recruitment and enrollment, while delivering high-quality data.
There’s no substitute for speed. Compared to traditional site-based studies, the Science 37 Metasite™ accelerates your study’s recruitment and start up, while enabling greater patient retention and inclusivity.
Limited Participation: Only 8% of patients participate in traditional clinical research.
Slower Execution: Average start-up time is 31.4 weeks, with 80% delayed from enrollment.
Poor Retention: On average, trials have a 70% retention rate.
Limited Diversity: Only an average of 14% non-white representation.
A Metasite exists alongside traditional sites, improving patient experience- enabling faster trials.
Use a data-driven, omnichannel approach that makes it easier to recruit and enroll patients.
Meet clinical trial deadlines without sacrificing quality.
The platform, people and processes designed to retain patients longer.
Generate a more real-world representation with robust recruitment and expansive networks.
The Science 37 Metasite™ leverages real-world prevalence data to deliver data-driven feasibility assessments and uses an omni-channel recruitment approach to select the best channel for reaching receptive patients. Interactive screeners and a Centralized Patient Engagement Center drive high-efficiency enrollment so that no patient is lost to follow up.
The Science 37 Metasite™ leverages real-world prevalence data to deliver data-driven feasibility assessments and uses an omni-channel recruitment approach to select the best channel for reaching receptive patients. Interactive screeners and a Centralized Patient Engagement Center drive high-efficiency enrollment so that no patient is lost to follow up.
The moment a study facilitator enters data and hits “submit”, the data is captured in the system and reflected in the patient journey without the need for manual re-entry.
The moment a study facilitator enters data and hits “submit”, the data is captured in the system and reflected in the patient journey without the need for manual re-entry.
Sponsors and CROs who partner with Science 37 get access to the full range of Metasite™ capabilities at scale.
150+
Trials Launched
3x
More Diversity than Traditional Sites
33M+
Patients Accesible
34k+
Physician Providers
(contracted for research)
IDC Real-World Evidence, Social Determinants of Health, and Digital Biomarkers in Driving Patient Recruitment, #US50382823, March 2023
GlobalData
Clinical Trial Sponsor
Clinical Trial Sponsor